ライフサイエンスコーパス: angiotensin II receptor

1 overexpress individual GRKs and the type 1A angiotensin II receptor.

2 y to nerves and myocytes, which both express angiotensin II receptors.

3 RGS5 modulates signaling through the angiotensin II receptor 1 and major Galphaq-coupled down

4 coding for components of the RAS (ACE gene, Angiotensin II receptor 1 gene, Angiotensinogen gene) in

5 tment of diabetic ZDF rats with losartan, an angiotensin II receptor-1 (Agtr1) antagonist, attenuated

6 nals TGF-beta1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition.

7 damage, and suppression of cardio-reparative Angiotensin II receptor 2 (Agtr2).

8 The angiotensin II receptor AGTR1, which mediates vasoconstr

9 nd differentiation via signaling through the angiotensin II receptors AGTR1 and AGTR2.

10 osome 3q in a region encompassing the type 1 angiotensin II receptor (AGTR1) gene.

11 tate optimal export trafficking of different angiotensin II receptors and export ability of each acid

12 The regulation of angiotensin II receptors and the two major subtypes (AT1

13 gical responses, contain the final effector (angiotensin II receptor), and respond to humoral, neural

14 tion to diabetic nephropathy; and renin, the angiotensin II receptor, and kallikrein because of their

15 armacologic agents that directly inhibit the angiotensin II receptor (angiotensin receptor blocker [A

16 Postburn administration of the angiotensin II receptor antagonist DuP753 significantly

17 e-blind treatment with eplerenone 50 mg, the angiotensin II receptor antagonist losartan 50 mg, or pl

18 sted whether losartan--a clinically approved angiotensin II receptor antagonist with noted antifibrot

19 Luminal 10(-8) M Dup 753 (an angiotensin II receptor antagonist) resulted in a 35% de

20 J6, we identified telmisartan, a widely used angiotensin II receptor antagonist, as a potent inhibito

21 ravitreal injection of saralasin, a specific angiotensin II receptor antagonist, had no significant e

22 12-week oral administration of losartan, an angiotensin II receptor antagonist, in patients with hea

23 o-OSA), all patients began treatment with an angiotensin II receptor antagonist, losartan, 50 mg dail

24 Losartan is a specific, nonpeptide angiotensin II receptor antagonist.

25 We assessed the role of the angiotensin-II-receptor antagonist losartan in patients

26 nsin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (AT1RA) slow the rat

27 ceutical compounds such as renin inhibitors, angiotensin II receptor antagonists and aldosterone anta

28 angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists in the treatment of

29 hiazides, beta-blockers, ACE inhibitors, and angiotensin II receptor antagonists) in fixed doses in w

30 eroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, and beta-lactam ant

31 Limited long-term data are available for the angiotensin II receptor antagonists.

32 Angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists are recommended for

33 angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney di

34 ACE inhibition and/or blocking of the angiotensin II receptor are recognized as first-line tre

35 This hypertension is abolished by selective angiotensin II receptor AT-1 antagonist at a low dose th

36 a competitive receptor antagonist of type I angiotensin II receptors at a dose that would block cent

37 a) and interleukin-1 beta up-regulate type 1 angiotensin II receptor (AT(1)) mRNA and protein in cult

38 Although 2 types of angiotensin II receptors (AT(1) and AT(2)) are upregulat

39 andesartan, an inverse agonist of the type 1 angiotensin II receptor (AT1 R), causes a concentration-

40 d by losartan, the first of the new class of angiotensin II receptor (AT1) antagonists.

41 ion of the seven-transmembrane domain type 1 angiotensin II receptor (AT1-R) but it also suppresses e

42 e effects of cAMP-elevating agents on type I angiotensin II receptor (AT1-R) mRNA levels were assesse

43 onist-induced desensitization of the type 1A angiotensin II receptor (AT1A-R), we have stably express

44 The type 1A angiotensin II receptor (AT1A-R), which mediates cardiov

45 The angiotensin II receptors AT1R and AT2R serve as key comp

46 Type I angiotensin II receptors (AT1R) are somewhat unique in t

47 pixel units (apu); P < 0.03), and increased angiotensin II receptor AT2 expression in the renal medu

48 drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with

49 Brooke et al. now report that combining angiotensin II receptor blockade by losartan with beta-b

50 The clinical effects of long-term angiotensin II receptor blockade compared with ACE inhib

51 iotensin-converting enzyme inhibition versus angiotensin II receptor blockade on survival in rats wit

52 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockade use (OR, 0.42; [95% CI,

53 and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockade use remained independen

54 ignificant difference between survival after angiotensin II receptor blockade with losartan and with

55 To determine whether specific angiotensin II receptor blockade with losartan offers sa

56 and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockade, were associated with t

57 Neither angiotensin II receptors blockade nor alpha and beta adr

58 , an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACE-I/ARB), and lipid-l

59 of trials have tested the hypothesis that an angiotensin II receptor blocker (ARB) could be as effect

60 he association of statin, ACE inhibitor, and angiotensin II receptor blocker (ARB) use with pneumonia

61 tensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), and diuretic medi

62 vasodilating beta blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults wi

63 rs, whereas angiotensin-converting enzyme or angiotensin II receptor blocker adherence was not associ

64 the use of converting enzyme inhibitors and angiotensin II receptor blocker emphasizing doses, effic

65 We aimed to assess the effect of the angiotensin II receptor blocker losartan on left ventric

66 of either angiotensin-converting enzyme plus angiotensin II receptor blocker or angiotensin-convertin

67 Treatment with the angiotensin II receptor blocker telmisartan improved glu

68 as provided new information into the role of angiotensin II receptor blocker therapy in patients who

69 Angiotensin II receptor blocker therapy may be protectiv

70 Angiotensin II receptor blocker therapy was associated w

71 ons, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, smoking cessation;

72 hly mean rate of 100 adverse events for 1000 angiotensin II receptor blocker users before and after g

73 nd, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice d

74 parative data on the long-term effects of an angiotensin II receptor blocker versus an angiotensin-co

75 n angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker were newly prescribed H-

76 in converting enzyme blocker, lisinopril, or angiotensin II receptor blocker, losartan, did not impro

77 imed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysf

78 enalapril, an ACE inhibitor, or L-158809, an angiotensin II receptor blocker.

79 n angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.

80 the angiotensin II receptor, or losartan, an angiotensin II receptor blocker.

81 lass, lower diastolic blood pressure, and no angiotensin II receptor blocker/angiotensin-converting e

82 otensin-converting-enzyme (ACE) inhibitor or angiotensin II-receptor blocker (ARB).

83 inhibitor (moderate-quality evidence) or an angiotensin II-receptor blocker (high-quality evidence)

84 and early nephropathy to receive either the angiotensin II-receptor blocker telmisartan (80 mg daily

85 ngiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker.

86 The angiotensin-II-receptor blocker irbesartan is effective

87 It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calciu

88 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (84.2%), and mineraloco

89 in II converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) presumably stimul

90 giotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), beta-blockers an

91 nsin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB).

92 iotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs) at discharge and

93 ensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for lowering blo

94 ensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) inhibit the reni

95 ensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), more effectivel

96 Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone antagon

97 EPHESUS have added insight into the role of angiotensin II receptor blockers and aldosterone in the

98 significant differences in adherence between angiotensin II receptor blockers and angiotensin-convert

99 s and beta-blockers and highest adherence to angiotensin II receptor blockers and angiotensin-convert

100 Angiotensin II receptor blockers are beneficial in patie

101 dies of neutral endopeptidase inhibitors and angiotensin II receptor blockers are described.

102 We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on ad

103 There was better adherence to angiotensin II receptor blockers compared with angiotens

104 The role of angiotensin II receptor blockers in patients with a syst

105 l studies are needed to assess the effect of angiotensin II receptor blockers in preclinical hypertro

106 e studies suggest that ACE inhibitors and/or angiotensin II receptor blockers may be effective treatm

107 Attenuation of TGF-beta signaling by angiotensin II receptor blockers may represent a mechani

108 sed case-control study indicates that use of angiotensin II receptor blockers might be associated wit

109 studies have suggested beneficial effects of angiotensin II receptor blockers on left ventricular hyp

110 The effect of angiotensin II receptor blockers on right ventricular (R

111 d mitral valves and we tested the effects of angiotensin II receptor blockers on TGF-beta signaling i

112 dings challenge the generally held view that angiotensin II receptor blockers reduce cardiac hypertro

113 reatitis and 61,637 controls, current use of angiotensin II receptor blockers was followed by a decre

114 te this variation, 7 of 8 classes (excluding angiotensin II receptor blockers) had at least 1 widely

115 and chronic use of statins or ACE inhibitors/angiotensin II receptor blockers) or plasma concentratio

116 Thiazide diuretics, angiotensin II receptor blockers, and ACE inhibitors may

117 tunately, several modern drugs (eg, statins, angiotensin II receptor blockers, angiotensin-converting

118 titis, by degree of severity, among users of angiotensin II receptor blockers, as compared to non-use

119 s (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, aldoste

120 arge angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, beta-blockers, and lip

121 s (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium

122 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, beta-blockers, thiazid

123 e of angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, lactates, renal replac

124 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers--have been shown to be

125 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

126 cal research suggests a protective effect of angiotensin II receptor blockers.

127 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

128 AD2/3 and p38 signaling and was inhibited by angiotensin II receptor blockers.

129 mg/d) already receiving maximal therapy with angiotensin II receptor blockers.

130 ranged from 28% for beta-blockers to 65% for angiotensin II receptor blockers.

131 The benefit of angiotensin II-receptor blockers (ARBs) in heart failure

132 eatment with TGF-beta antagonists, including angiotensin II-receptor blockers (ARBs).

133 ative risk, 0.65 [95% CI, 0.49 to 0.88]) and angiotensin II-receptor blockers (relative risk, 0.77 [C

134 but they support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in p

135 ectly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-convert

136 The strength of evidence was rated high for angiotensin II-receptor blockers and statins, moderate f

137 angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers, and in patients with a

138 angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers.

139 in-converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs) have been increa

140 ensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) have specific re

141 sonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, and perhaps angiotensi

142 t they may not be as effective as diuretics, angiotensin-II receptor blockers, or ACE inhibitors; how

143 e ER and transport to the plasma membrane of angiotensin II receptors, but not adrenergic receptors.

144 ng neoplasia, we have examined the effect of angiotensin II receptor deficiency on 4-(methylnitrosami

145 nregulated collectrin expression in a type 1 angiotensin II receptor-dependent manner.

146 tein kinase C inhibitor Ro-31-8425, a mutant angiotensin II receptor (DRY/AAY), and a mutant angioten

147 The decrease of angiotensin II receptor expression may reflect the loss

148 tudied the effect of ischemia on hippocampal angiotensin II receptor expression, 1, 4 and 15 days aft

149 se in sodium transport, and up-regulation of angiotensin II receptor expression, of which expression

150 binds several Galpha subunits immunoselected angiotensin II receptor-Galpha complexes.

151 he availability of selective antagonists for angiotensin II receptors has focused interest on the gen

152 (AGT), and the type 1 (AT1) and type 2 (AT2) angiotensin II receptors, has been implicated in the pat

153 xpression of the AT1 and AT2 subtypes of the angiotensin II receptor in ventricular myocardium taken

154 n of renin-angiotensin system components and angiotensin II receptors in cardiac tissue suggests the

155 The number of angiotensin II receptors in normal liver was significant

156 the end of lactation had a higher density of angiotensin II receptors in the organum vasculosum lamin

157 edly reduced beta(2)-adrenergic receptor and angiotensin II receptor internalization and impaired act

158 Biased agonism of the angiotensin II receptor is known to promote cardiac cont

159 g-term beta-arrestin 2-biased agonism of the angiotensin II receptor may be a viable approach to the

160 f intact myofibrils, these data suggest that angiotensin II receptor-mediated activation of PKC may p

161 Type 1 angiotensin II receptor mRNA also approached a significa

162 In the dentate gyrus, angiotensin II receptor mRNA and angiotensin II binding

163 Type 1 angiotensin II receptor mRNA expression also correlated

164 Type 1 angiotensin II receptor mRNA expression at biopsy direct

165 Type 1 angiotensin II receptor mRNA expression significantly co

166 No changes in angiotensin II receptor mRNA or binding were detected 1

167 Angiotensin II receptor mRNA was found in the pyramidal

168 angiotensin II hepatoma may relate a loss of angiotensin II receptor on tumor neovasculature.

169 0067, a beta-arrestin 2-biased ligand of the angiotensin II receptor, or losartan, an angiotensin II

170 use model of cerebral malaria, modulation of angiotensin II receptors produced similar effects, leadi

171 receptor expression may reflect the loss of angiotensin II receptor-producing neurons rather than a

172 d type, P = 7.8 x 10(-40)), which suppresses angiotensin II receptor signaling via allosteric transin

173 ingestion rather than from a destruction of angiotensin II receptor sites that directly provoke salt

174 tensin II infusion in hepatoma by evaluating angiotensin II receptor status in normal liver, hepatoma

175 The angiotensin II receptor status in the normal liver, hepa

176 trol mice, while the contractile response to angiotensin II receptor stimulation was unchanged.

177 These actions are mediated through angiotensin II receptors (subtype AT1), which activate t

178 s focused interest on the gene expression of angiotensin II-receptor subtypes in the human heart.

179 cation of Telmisartan (an antagonist for the angiotensin II receptor) through copper-mediated C-H ami

180 data analysis identified one important gene, angiotensin II receptor type 1 (AGTR1), in the Ca2+/AT-I

181 Substantial evidence indicates that the angiotensin II receptor type 1 (AT1 R) is inherently mec

182 Intrarenal administration of angiotensin II receptor type 1 (AT1) receptor antagonist

183 al collection and identified telmisartan, an angiotensin II receptor type 1 (AT1R) blocker, as a pote

184 027, a beta-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), stimulates acute

185 it intracellular calcium release mediated by angiotensin II receptor type 1 (AT1R).

186 of blood pressure via angiotensin II and the angiotensin II receptor type 1 (AT1R).

187 r for advanced glycation end product [RAGE], angiotensin II receptor type 1 [AT(1)R]), p47(phox) NADP

188 This reduction makes angiotensin II receptor type 1 a promising therapeutic t

189 angiotensin-converting enzyme gene, and the angiotensin II receptor type 1 and receptor type 2 genes

190 giotensin II and substance P and through the angiotensin II receptor type 1 and substance P neurokini

191 An angiotensin II receptor type 1 antagonist inhibited mech

192 window of opportunity was tested by delaying angiotensin II receptor type 1 inhibition for 30 mins, 1

193 The results indicate that angiotensin II receptor type 1 plays a key role in the d

194 Inhibition of angiotensin II receptor type 1 significantly attenuated

195 Angiotensin II receptor type 1 was inhibited using cande

196 Blockage of angiotensin II receptor type 1 with 0.1 mg/kg candesarta

197 Inhibition of angiotensin II receptor type 1 with a delay of up to 4 h

198 renin, angiotensin I-converting enzyme, and angiotensin II receptor type 1) to interindividual varia

199 induced sympathoexcitation is independent of angiotensin II receptor type 1, oxytocin, ionotropic glu

200 termed AT(1)-AAs, that bind and activate the angiotensin II receptor type 1a (AT(1) receptor).

201 T-PCR assays revealed the expression of both angiotensin II receptor type 1A (AT(1A)) and angiotensin

202 Expression of angiotensin II receptor type 1A decreased by 42% within

203 angiotensin II receptor type 1A (AT(1A)) and angiotensin II receptor type 1B (AT(1B)) subtypes in fre

204 KEY POINTS: The angiotensin II receptor type 1b (AT1 Rb ) is the primary

205 rs after controlled cortical impact, whereas angiotensin II receptor type 1B expression increased to

206 ), transforming growth factor beta (47%) and angiotensin II receptor type 2 (132%), 27% less elastin

207 In contrast, similar doses of the angiotensin II receptor type 2 (AT2) receptor ligand CGP

208 imal models suggest that in the vasculature, angiotensin II receptor type 2 (AT2-R) expression may be

209 Angiotensin II receptor type I (AT(II)R(1)), induced by

210 myosin (CM), collagen V (Col V), agrin, and angiotensin II receptor type I (AT1).

211 e reversed within minutes by pharmacological angiotensin-II receptor type 1 (AT1 R) blockade.

212 pathology and can be reversed acutely by an angiotensin-II receptor type 1 antagonist.

213 In addition, association of PKCalpha and angiotensin-II receptor, type 1, with Cav-3 was disrupte

214 he expression, localization and transport of Angiotensin II receptor types in the rat sciatic nerve p

215 In situ binding analysis revealed that angiotensin II receptors were mainly on the smooth muscl

216 Angiotensin II receptors were measured by saturation bin

217 Chronic (5 days) blockade of angiotensin II receptors with losartan elevated plasma r